Norka Perez Romero
Nurse Practitioner · Jacksonville, FLNPI 1427407022
Payments from drug & device makers
Across 138 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$780
- AstraZeneca$430
- AbbVie$361
- Boston Scientific$306
- Dexcom, Inc.$207
- Biohaven Pharmaceutical Holding Company Ltd.$190
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,562100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $780 |
| AstraZeneca(2 entities) | 8 | $430 |
| AbbVie | 16 | $361 |
| Boston Scientific | 9 | $306 |
| Dexcom, Inc. | 4 | $207 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $190 |
| GSK | 8 | $146 |
| Otsuka America Pharmaceutical, Inc. | 4 | $129 |
| Corcept Therapeutics | 1 | $115 |
| Medtronic | 2 | $83 |
| Lilly USA, LLC | 5 | $77 |
| Novartis | 4 | $72 |
| Pfizer | 5 | $69 |
| Eisai Inc. | 3 | $52 |
| Amgen | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Abbott | 2 | $42 |
| Nevro Corp. | 2 | $42 |
| Nestle Healthcare Nutrition Inc. | 2 | $41 |
| Bayer | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Exact Sciences | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Astellas Pharma US Inc | 2 | $28 |
| Philips North America LLC | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Merck | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,562 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $140,994 |
| MounjaroTirzepatide | 63 | $77,397 |
| JardianceEmpagliflozin | 60 | $60,602 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $44,383 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $35,576 |
| EliquisApixaban | 40 | $32,126 |
| FarxigaDapagliflozin Propanediol | 39 | $31,371 |
| LinzessLinaclotide | 43 | $24,279 |
| MyrbetriqMirabegron | 26 | $17,997 |
| JanuviaSitagliptin Phosphate | 15 | $15,137 |
| EntrestoSacubitril/Valsartan | 11 | $13,112 |
| Diclofenac Sodium | 37 | $11,793 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $9,629 |
| Spiriva RespimatTiotropium Bromide | 13 | $9,614 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 180 | $6,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $780 | $140,994124 claims |
| Lilly USA, LLCMounjaro | $77 | $77,39763 claims |
| GSKTrelegy Ellipta | $146 | $35,57627 claims |
| AstraZenecaFarxiga, Symbicort | $430 | $35,52250 claims |
| PfizerEliquis | $69 | $32,12640 claims |
| AbbVieLinzess | $361 | $24,27943 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $17,99726 claims |
| MerckJanuvia | $18 | $15,13715 claims |
| NovartisEntresto | $72 | $13,11211 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $1,51893 claims |
| Sanofi-aventis U.S. LLCLantus | $20 | $1,50912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Jacksonville
- Mary FarrJacksonville$66K
- Stacey KellyJacksonville$22K
- Jean Sheridan-YoungJacksonville$22K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.